CD274 and neoplasm: Patients with low expression of PD-L1 in tumor and high expression of PD-L1 on TILs had the best prognosis with 5-year PFS and OS 95.9% and 100%, respectively, while patients with high expression of PD-L1 in tumor and low expression of PD-L1 on TILs had the worst prognosis with 5-year PFS and OS 72.2% and 72.2%, respectively (HR = 0.13, p = 0.0078 for PFS and HR < 0.01, p = 0.0051 for OS).